Cost-effectiveness of clozapine. A UK clinic-based study

British Journal of Psychiatry

Volumn 171, Issue AUG., 1997, Pages 125-130

  Aitchison, Katherine J ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM CARBONATE; OLANZAPINE; PROPRANOLOL; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; CAREGIVER; CLINICAL ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EMPLOYMENT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCOME; ONSET AGE; OUTPATIENT CARE; QUALITY OF LIFE; SCHIZOIDISM; SCHIZOPHRENIA; UNITED KINGDOM;

EID: 0030796665     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.171.2.125     Document Type: Article

References (24)

1. Department of Health, Education and Welfare (1974) Abnormal Involuntary Movements Scale (AIMS). Washington, DC: Alcohol, Drug Abuse, and Mental Health Administration; Department of Health Administration; Department of Health, Education and Welfare.
2. Allebeck, P. (1989) Schizophrenia: a life-shortening disease. Schizophrenia Bulletin, 15, 81-89.
3. Anderson, C., Connelly, J., Johnstone, E. C., et al (1991) Disabilities and circumstances of schizophrenic patients: V. Cause of death. British Journal of Psychiatry, 159 (suppl. 13), 30-33.
4. Beecham, J. F. (1995) Collecting and estimating costs. In The Economic Evaluation of Mental Health Services (ed. M. R. J. Knapp), pp. 61-82. Aldershot: Arena.
5. Davies, L. M. & Drummond, M. F. (1994) Economics and schizophrenia: the real cost. British Journal of Psychiatry, 165 (suppl. 25), 18-21.
6. Department of Health (1994) Burdens of Disease. A Discussion Document. London: DoH.
7. Endicott, J., Spitzer, R. L., Fleiss, J. L., et al (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33, 766-771.
8. Guest, J. F., Hart, W. M., Cookson, R. F., et al (1996) Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics, 10, 59-67.
9. Heinrichs, D. N., Hanton, T. E. & Carpenter, W. T. (1984) The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388-398.
10. Honigfeld, G. & Patin, J. (1990) A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry, 41, 882-885.
11. Johnstone, E. C., Owens, D. G. C. & Leary, J. (1991) Disabilities and circumstances of schizophrenic patients. VI: Comparison of the 1975-85 cohort with the 1970-75 cohort. British Journal of Psychiatry, 159 (suppl. 13), 34-36.
12. Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
13. _ (1992) Clinical efficacy of clozapine in treatmentrefractory schizophrenia: an overview. British Journal of Psychiatry, 140 (supp. 17), 41-45.
14. Lieberman, J. A., Safferman, A. Z., Pollack, S., et al (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry, 151, 1744-1752.
15. Martin, C. (1996) Impact of olanzapine on quality of life in schizophrenia. European Journal of Psychiatry, 11 (suppl. 4), 252.
16. Matheson, L. A., Cook, H. M., McKenna, P., et al (1994) Value for money for patients with schizophrenia. British Journal of Medical Economics, 7, 25-34.
17. Maynard, A. (1993) Cost management: the economists viewpoint. British Journal of Psychiatry, 163 (suppl. 20), 7-13.
18. Meltzer, H.Y., Cola, P., Way, L., et al (1993) Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.
19. Netten, A. (1994) Unit Costs of Community Care 1994. Canterbury: Personal Social Services Research Unit.
20. Overall, J. E. & Gorham, D. E. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799-812.
21. Prudo, R. & Bluhm, H. M. (1987) Five-year outcome and prognosis in schizophrenia. British Journal of Psychiatry, 150, 345-354.
22. Reid, W. H., Mason, M. & Topral, M. (1994) Savings in hospital bed days related to treatment with clozapine. Hospital and Community Psychiatry, 45, 261-264.
23. Revicki, D. A., Luce, B. R., Weschler, J. M., et al (1990) Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41, 850-854.
24. Royal College of Psychiatrists (1996) Report of the Confidential Inquiry into Homicides and Suicides by Mentally Ill People. London: Royal College of Psychiatrists.